SAFETY AND PHARMACOKINETICS OF ABI-H3733, A NOVEL 2nd GENERATION HBV CORE PROTEIN INHIBITOR: RESULTS FROM A PHASE 1a STUDY IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Gane, Edward J. [1 ]
Schwabe, Christian [2 ]
Alves, Katia [3 ]
Evanchik, Marc [3 ]
Ma, Julie [3 ]
Zomorodi, Katie [3 ]
Knox, Steven J. [3 ]
Stamm, Luisa M. [3 ]
机构：
[1] Auckland City Hosp, Liver Transplant Unit, Auckland, New Zealand
[2] New Zealand Clin Res, Auckland, New Zealand
[3] Assembly Biosci Inc, San Francisco, CA USA
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
842
引用
收藏
页码：516A / 516A
页数：1
相关论文
共 48 条
  • [41] Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects
    Liu, Jian
    Zhao, Qingwei
    Zhai, You
    Wu, Xia
    Kai, Jiejing
    Ruan, Jie
    Wu, Minglan
    Wu, Meijia
    Zhou, Zhuojun
    Yan, Yuemei
    Wu, Jinzi J.
    Qiu, Yunqing
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024,
  • [42] Safety, Pharmacokinetics, and Biologic Activity of ND-L02-s0201, a Novel Targeted Lipid-Nanoparticle to Deliver HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis: Interim Results from Clinical Phase 1b/2 Studies
    Lawitz, Eric
    Tanaka, Yasunobu
    Poordad, Fred
    Gutierrez, Julio A.
    Carr, Kathy
    Ying, Wenbin
    Niitsu, Yoshiro
    Maruyama, Kageshi
    HEPATOLOGY, 2015, 62 : 909A - 909A
  • [43] EFFICACY AND SAFETY OF LESINURAD (RDEA594), A NOVEL URAT1 INHIBITOR, IN COMBINATION WITH ALLOPURINOL IN ALLOPURINOL-REFRACTORY GOUT PATIENTS: RESULTS FROM A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, PHASE 2B EXTENSION STUDY
    Perez-Ruiz, F.
    Sundy, J.
    Krishnan, E.
    Hingorani, V.
    Welp, J.
    Rodgers, T.
    Manhard, K.
    Cravets, M.
    Hagerty, D.
    Quart, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 439 - 439
  • [44] RESULTS OF A PHASE 1, 4-PERIOD CROSSOVER, PLACEBO-CONTROLLED, RANDOMIZED, SINGLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-925, A NOVEL OREXIN 2 RECEPTOR AGONIST, IN SLEEP-DEPRIVED HEALTHY ADULTS, UTILIZING MODAFINIL AS AN ACTIVE COMPARATOR
    Evans, R.
    Hazel, J.
    Faessel, H.
    Wu, J.
    Hang, Y.
    Alexander, R.
    Rosen, L.
    Hartman, D.
    SLEEP MEDICINE, 2019, 64 : S106 - S106
  • [45] Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
    Doger de Speville, Bernard
    Felip, Enriqueta
    Forster, Martin
    Majem, Margarita
    Bajaj, Pawan
    Peguero, Julio Antonio
    Carcereny, Enric
    Krebs, Matthew G.
    Mukherjee, Uma
    Mueller, Christian
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naive PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment
    Zhang, Fengkui
    Zhang, Li
    Yang, Chen
    Yue, Changhe
    Ma, Jay
    He, Chaomei
    Tsui, Ping
    Weng, Qing Yu Christina
    Fu, Helen
    Yan, Hui
    Song, Wenru
    Han, Bing
    BLOOD, 2024, 144 : 2699 - 2700
  • [47] Combination of Oral Nanatinostat, a Novel Histone Deacetylase Inhibitor, and the Oral Anti-Viral, Valganciclovir, Is Active in Relapsed/Refractory Epstein-Barr Virus-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results From a Phase 1b/2a Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 19
  • [48] Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study
    Porcu, Pierluigi
    Haverkos, Brad M.
    Alpdogan, Onder
    Capra, Marcelo
    Feldman, Tatyana A.
    Brem, Elizabeth
    Vallurupalli, Anusha
    Brammer, Jonathan E.
    Schriefer, Ana
    Pereira, Juliana
    Tulpule, Anil
    Barta, Stefan K.
    Bryan, Locke J.
    Trauger, Richard
    Obrzut, Sebastian
    Gutheil, John
    Katkov, Afton
    McRae, Robert
    Royston, Ivor
    Faller, Douglas V.
    BLOOD, 2019, 134
12345